李佳時(shí)

【摘要】 目的 探討長(zhǎng)春西汀聯(lián)合川芎嗪綜合治療急性腦梗死的臨床療效及不良反應(yīng)。方法 50例
急性腦梗死患者, 根據(jù)治療方法的不同分為對(duì)照組(實(shí)施長(zhǎng)春西汀注射液治療)和觀察組(實(shí)施長(zhǎng)春西汀注射液聯(lián)合川芎嗪綜合治療), 各25例。觀察比較兩組患者的臨床療效及不良反應(yīng)發(fā)生情況。結(jié)果 觀
察組患者總有效率為92%, 顯著高于對(duì)照組的68%, 差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);觀察組患者不良反應(yīng)發(fā)生率明顯低于對(duì)照組, 差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 給予急性腦梗死患者長(zhǎng)春西汀注射液聯(lián)合川芎嗪綜合治療的臨床療效顯著, 能夠減少不良反應(yīng)發(fā)生, 值得臨床推廣使用。
【關(guān)鍵詞】 長(zhǎng)春西汀;川芎嗪;急性腦梗死;臨床療效;不良反應(yīng)
DOI:10.14163/j.cnki.11-5547/r.2018.02.042
Analysis of clinical efficacy and adverse reaction of vinpocetine combined with ligustrazine for comprehensive treatment of acute cerebral infarction LI Jia-shi. Anshan Iron and Steel Group General Hospital, Anshan 114000, China
【Abstract】 Objective To discuss the clinical efficacy and adverse reaction of vinpocetine combined with ligustrazine for comprehensive treatment of acute cerebral infarction. Methods A total of 50 acute cerebral infarction patients were divided by different treatment methods into control group (received vinpocetine injection) and observation group (received comprehensive therapy of vinpocetine injection and ligustrazine), with 25 cases in each group. Observation and comparison were made on clinical efficacy and occurrence of adverse reactions between two groups. Results The observation group had obviously higher total effective rate as 92% than 68% in the control group, and the difference was statistically significant (P<0.05). The observation group had obviously lower incidence of adverse reactions than the control group, and the difference was statistically significant (P<0.05). Conclusion Comprehensive therapy of vinpocetine injection and ligustrazine shows remarkable clinical efficacy in treating acute cerebral infarction patients can reduce the occurrence of adverse reactions, and is worthy of clinical promotion and application.
【Key words】 Vinpocetine; Ligustrazine; Acute cerebral infarction; Clinical efficacy; Adverse reaction
急性腦梗死具有致殘、致死、復(fù)發(fā)率高等特點(diǎn), 是神經(jīng)內(nèi)科最常見的腦血管疾病之一[1], 其發(fā)病機(jī)制為血管內(nèi)膜損傷或者腦動(dòng)脈粥樣硬化使得患者的腦動(dòng)脈管腔狹窄, 最終形成血栓或者栓死, 引起患者的腦組織缺氧、缺血、壞死、形成神經(jīng)功能障礙[2], 且該病多發(fā)于中老年人[3]。本文探討長(zhǎng)春西汀聯(lián)合川芎嗪綜合治療急性腦梗死的臨床療效及不良反應(yīng), 從而能夠?yàn)榕R床醫(yī)療工作提供相應(yīng)的指導(dǎo)和參考, 現(xiàn)報(bào)告如下。
1 資料與方法
1. 1 一般資料 選擇本院2015年6月~2016年6月收治的50例急性腦梗死患者為觀察對(duì)象, 根據(jù)治療方法的不同分為對(duì)照組和觀察組, 各25例。對(duì)照組患者男14例, 女11例;
年齡43~88歲, 平均年齡(67.3±6.9)歲;病程4.5~18.2 h, 平均病程(10.3±1.2)h。觀察組患者男13例, 女12例;年齡42~89歲, 平均年齡(67.8±7.1)歲;病程4.0~18.5 h, 平均病程(10.0±1.5)h。兩組患者一般資料比較, 差異無統(tǒng)計(jì)學(xué)意義(P>0.05), 具有可比性。
1. 2 方法 所有患者進(jìn)行基礎(chǔ)治療, 預(yù)防感染、降顱壓、血壓控制、維持水和電解質(zhì)平衡等。基于此, 對(duì)照組患者單純進(jìn)行長(zhǎng)春西汀注射液治療, 將20 mg長(zhǎng)春西汀加入250 ml生理鹽水中, 靜脈滴注。觀……